Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific MeetingGlobeNewsWire • 10/23/22
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Phathom Pharmaceuticals, Inc. - PHATNewsfile Corp • 08/13/22
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 08/12/22
ROSEN, Global Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 08/09/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/08/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/05/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 08/05/22
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/05/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/04/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of InvestorsBusiness Wire • 08/03/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 08/03/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/03/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of InvestorsBusiness Wire • 08/03/22
The Law Offices of Frank R. Cruz Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of InvestorsBusiness Wire • 08/03/22
EQUITY ALERT: Rosen Law Firm Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation – PHATBusiness Wire • 08/02/22
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/02/22
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare ConferenceGlobeNewsWire • 06/01/22
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022GlobeNewsWire • 05/24/22
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business UpdatesGlobeNewsWire • 05/10/22
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive CapitalGlobeNewsWire • 05/04/22
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in AdultsGlobeNewsWire • 05/03/22
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/22